139
Liver-Targeting Tolerogenic Nanoparticles
University of California - Los Angeles
Nanoparticle
Inflammatory disease
Hit To Lead or Lead Optimization
• NPOVA induced abundant TFG-β, IL-4, and IL-10 production, which was further increased by surface ligands.
• NPOVA suppressed anti-OVA IgE responses, airway eosinophilia and TH2 cytokine production in the bronchoalveolar lavage fluid.
• Antigen specific interventions for allergies and autoimmune disorders—two groups of disorders characterized by patients’ hyperactive immune response against non-pathogenic bodies—are limited in number and efficacy.
• UCLA inventors present a novel nanoparticle based therapeutic platform that induces immune tolerance towards a predetermined antigen in animal models. Through targeting of tolerogenic antigen presenting cells in the liver, researchers demonstrated, as a proof of principle, that administration of nanoparticles to mouse models of asthma and anaphylaxis can reduce these potentially fatal systemic allergic disorders.
• There is also preliminary evidence that the same is true in animal models for rheumatoid arthritis, lupus, and type I diabetes. Importantly, the tolerogenic effect can be obtained by using intact, antigens or representative epitopes in these disease models, thereby avoiding the need for nonspecific immunosuppression or immune modulatory therapies. The tolerogenic nanoparticle platform is earmarked for treatment of a wide range of allergic disorders and autoimmune diseases.
WO2021096972A1
Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model. ACS Nano. (2019)
